Drugs / Inhaled treprostinil
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07116681 | Oct 2025 → Jul 2027 expected | pulmonary hypertension | University of California, San Diego | Not yet recruiting | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00147199 | Jun 2005 → Oct 2007 | pulmonary hypertension | United Therapeutics | Completed | Met primary |
Press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inhaled treprostinil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07116681 ↗ |
| Route | Inhaled | “Administration of study medication was performed by inhalation with the OPTINEB™ ultrasonic nebulizer.” NCT00147199 ↗ |